226950.KQ
OliX Pharmaceuticals,Inc
KOE · Healthcare · Biotechnology · KR
KRW 91,800.00
−8.38%Margins
Gross margin
87.2%
EBITDA margin
-287.7%
EBIT margin
-304.7%
Net margin
-102.9%
FCF margin
-234.8%
-5.9%
Return on equity
-5.1%
Return on assets
-16.1%
Return on invested capital
0.06x
Asset turnover
-KRW 30.1B
Cash from operations
KRW 10.6K
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026